MedPath

A clinical trial to study the efficacy of the drug misoprostol administered rectally in reducing excessive bleeding after normal delivery

Recruiting
Conditions
Women with singleton pregnancy undergoing normal vaginal delivery
Registration Number
CTRI/2014/08/004910
Lead Sponsor
DrSMCSIMedical college
Brief Summary

This study is a randomized double blind placebo controlled trial to find the efficacy of 400mcg of rectal Misoprostol given after the delivery of the baby (in addition to standard dose of 10 units Oxytocin IM injection), in reducing postpartum haemorrhage in 320 patients undergoing vaginal delivery in Dr SM CSI Medical College Hospital for a period of one year. The primary outcome measures will be fall in haemoglobin and PCV levels after 24 hours of delivery. The secondary outcome will be duration of third stage of labour

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Female
Target Recruitment
320
Inclusion Criteria

women with singleton pregnancy cephalic presentation >28 weeks of gestational age Hb>10gms.

Exclusion Criteria

patients undergoing cesarean section and instrumental delivery malpresentation multiple pregnancy past history of post partum haemorrhage coagulopathies heart disease/renal disease placenta previa/abruptio placenta.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
fall in haemoglobin and PCV levels24 hours
Secondary Outcome Measures
NameTimeMethod
Duration of third stage of labour

Trial Locations

Locations (1)

Labour Room

🇮🇳

Thiruvananthapuram, KERALA, India

Labour Room
🇮🇳Thiruvananthapuram, KERALA, India
Dr Ranjula Golda Lysander R
Principal investigator
9443253672
ranjulasandeep@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.